Want to see GB:GENF full AI Analyst Report?
Top Page
Genflow Biosciences Plc
(LSE:GENF)
Select Model
Select Model
Rating:50Neutral
Price Target:
2.00 p
▼(-11.11% Downside)
Action:Reiterated
Date:05/04/26
The score is held down primarily by very weak financial performance (pre-revenue, ongoing losses, negative equity, and continued cash burn). Technicals provide a meaningful offset with a clear uptrend and positive momentum, while valuation remains constrained by loss-making status and no dividend data.
Positive Factors
No financial debt
Having zero financial debt lowers immediate refinancing risk and preserves flexibility to raise equity or secure non‑debt funding. Over a 2–6 month horizon this reduces liquidity stress, gives management optionality to fund R&D, and avoids interest burdens that accelerate cash depletion.
Negative Factors
Pre-revenue and operating losses
Being pre‑revenue with persistent operating losses and negative gross profit means the company lacks internal cash generation and must repeatedly access external capital. This structurally constrains the pace of development, increases execution risk for pipelines, and raises dilution probability over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
No financial debt
Having zero financial debt lowers immediate refinancing risk and preserves flexibility to raise equity or secure non‑debt funding. Over a 2–6 month horizon this reduces liquidity stress, gives management optionality to fund R&D, and avoids interest burdens that accelerate cash depletion.
Read all positive factors
Genflow Biosciences Plc (GENF) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£10.90M
Dividend YieldN/A
Average Volume (3M)1.73M
Price to Earnings (P/E)―
Beta (1Y)0.02
Revenue GrowthN/A
EPS Growth29.79%
CountryUK
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding566,409,800
10 Day Avg. Volume2,042,393
30 Day Avg. Volume1,733,703
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-14.33
Price to Sales (P/S)0.00
P/FCF Ratio-5.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Genflow Biosciences Plc Business Overview & Revenue Model
Company Description
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapy targeting the upstream biology of aging in the United Kingdom and Belgium. The company operates as a pre-clinical biotechnology compan...
How the Company Makes Money
null...
Genflow Biosciences Plc Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.09K | -1.20K | -1.03K | -130.00 | 0.00 |
| EBITDA | -2.00M | -1.59M | -1.80M | -1.33M | -988.10K |
| Net Income | -1.42M | -1.59M | -1.63M | -1.34M | -988.29K |
Balance Sheet | |||||
| Total Assets | 452.39K | 385.91K | 1.07M | 2.62M | 276.55K |
| Cash, Cash Equivalents and Short-Term Investments | 111.79K | 278.68K | 683.97K | 2.36M | 224.00K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.00M | 788.92K | 345.74K | 250.99K | 221.43K |
| Stockholders Equity | -550.78K | -403.01K | 725.91K | 2.37M | 55.12K |
Cash Flow | |||||
| Free Cash Flow | -1.44M | -1.08M | -1.66M | -1.37M | -747.38K |
| Operating Cash Flow | -1.44M | -1.08M | -1.66M | -1.37M | -747.38K |
| Investing Cash Flow | 0.00 | 0.00 | -2.44K | -2.48K | 198.50K |
| Financing Cash Flow | 1.31M | 656.63K | 0.00 | 3.50M | 783.71K |
Genflow Biosciences Plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £10.90M | -5.88 | 377.33% | ― | ― | 29.79% | |
44 Neutral | £13.77M | -7.47 | -210.32% | ― | -11.43% | 23.40% | |
43 Neutral | £81.30M | -4.82 | -116.21% | ― | 81.46% | -15.88% | |
41 Neutral | £2.49M | -3.24 | -89.43% | ― | 91.27% | 60.98% | |
40 Underperform | £16.41M | -7.92 | -213.66% | ― | 13.42% | 65.63% | |
39 Underperform | £4.29M | -0.26 | -316.67% | ― | 33.37% | 86.41% |
* Healthcare Sector Average
GB:GENF
Genflow Biosciences Plc
2.00
1.33
196.30%
GB:OBD
Oxford BioDynamics
0.11
-0.48
-81.90%
GB:PYC
Physiomics
0.55
0.09
18.28%
GB:FAB
Fusion Antibodies Plc
10.75
4.00
59.26%
GB:4BB
4basebio UK Societas
525.00
-475.00
-47.50%
GB:APTA
Aptamer Group Plc
0.48
0.07
18.75%
Genflow Biosciences Plc Corporate Events
Business Operations and StrategyExecutive/Board Changes
Genflow advances SIRT6 longevity platform with positive dog data and new partnerships
Positive
Jul 13, 2026
Genflow Biosciences reported that its SIRT6-centric longevity platform is progressing on schedule, highlighted by positive interim data from the SLAB trial in aged beagles showing improved survival, sustained benefits at three months and a favoura...
Business Operations and StrategyShareholder Meetings
Genflow Wins Strong Shareholder Backing for Governance and New Share Scheme
Positive
Jun 29, 2026
Genflow Biosciences reported that shareholders approved all resolutions at its latest Annual General Meeting, signaling broad support for the company’s governance and strategic direction. Investors endorsed the 2025 annual report, directors&...
Business Operations and Strategy
Genflow’s Chair to Spotlight Longevity and RNA Therapeutics at BIO 2026
Positive
Jun 22, 2026
Genflow Biosciences said its independent non-executive chairman, Gad Berdugo, will represent the longevity-focused biotech at the BIO International Convention 2026 in San Diego. He is scheduled to join a panel on RNA therapeutics, examining where ...
Business Operations and Strategy
Genflow to Unveil Key Beagle Longevity Trial Data at Animal Summit 2026
Positive
Jun 17, 2026
Genflow Biosciences will present data from its SLAB (Sarcopenia and Longevity in Aged Beagles) clinical study at the Animal Longevity Summit 2026 in Toronto, highlighting the potential of its centenarian SIRT6 gene therapy to address multiple hall...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Genflow Sets June AGM and Announces Board Change Amid Longevity R&D Push
Neutral
Jun 4, 2026
Genflow Biosciences Plc, a UK-based longevity-focused biotech with operations in Belgium, is developing gene therapies targeting age-related diseases, led by its SIRT6-based candidate GF-1002 and associated clinical programmes in aged dogs and in ...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Genflow Biosciences expands share capital after warrant exercises
Positive
May 8, 2026
Genflow Biosciences announced the exercise of warrants leading to the issuance of 30,756,577 new ordinary shares, raising gross proceeds of approximately £359,375 to support its operations. The new shares, issued following warrant exercises a...
Business Operations and StrategyPrivate Placements and Financing
Genflow Advances SIRT6 Longevity Pipeline as Funding and Canine Trial Progress Bolster Position
Positive
Apr 30, 2026
Genflow Biosciences reported significant operational progress in 2025, highlighting its canine SLAB trial in aged beagles, which advanced without safety issues and is expected to complete by July 2026, and early partnering talks with major animal ...
Business Operations and Strategy
Genflow widens Tier-1 animal health review of canine gene therapy
Positive
Apr 28, 2026
Genflow Biosciences has expanded its network of confidentiality agreements with additional Tier-1 global animal health companies to review data from its canine SIRT6 centenarian gene therapy programme. The move follows previously disclosed positiv...
Business Operations and Strategy
Genflow Secures Fully Funded LNP Collaboration With Acuitas to Advance SIRT6 Gene Therapy
Positive
Apr 20, 2026
Genflow Biosciences has entered a strategic technology collaboration with Acuitas Therapeutics, gaining fully funded, non-dilutive access to Acuitas’ clinically validated lipid nanoparticle platform to deliver its SIRT6 mRNA payload. The dea...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.